##4071488
In	in	ii
recent	recent	jj
years	year	nnt2
there	there	ex_rl
has	have	vhz
been	be	vbn
a	a	at1
dramatic	dramatic	jj
increase	increase	nn1
in	in	ii
the	the	at
abuse	abuse	nn1
of	of	io
and	and	cc
dependency	dependency	nn1
on	on	ii
prescription	prescription	nn1
opioid	opioid	nn1_jj
pain	pain	nn1
medications	medication	nn2
(	(	y
also	also	rr
known	know	vvn
as	as	ii
narcotics	narcotic	nn2
)	)	y
.	.	y
Viewed	view	vvn_vvd
as	as	csa_rg@_ii@
safer	safe	jjr_rrr
than	than	csn
street	street	nn1
drugs	drug	nn2
like	like	ii
heroin	heroin	nn1
,	,	y
prescription	prescription	nn1
pain	pain	nn1
pill	pill	nn1
misuse	misuse	nn1
is	be	vbz
on	on	ii
the	the	at
increase	increase	nn1
in	in	ii
all	all	db
age	age	nn1_vv0@
ranges	range	nn2_vvz
.	.	y
Frequently	frequently	rr
abused	abuse	vvn_jj@
prescription	prescription	nn1
pain	pain	nn1
medications	medication	nn2
include	include	vv0
hydrocodone	hydrocodone	nn1
(	(	y
Lorcet	lorcet	np1_vv0_nn1
,	,	y
Lortab	lortab	np1
,	,	y
Vicodin	vicodin	np1
)	)	y
,	,	y
oxycodone	oxycodone	nn1_vv0
(	(	y
OxyContin	oxycontin	np1
,	,	y
Percocet	percocet	np1_vv0_nn1
,	,	y
Percodan	percodan	np1
)	)	y
,	,	y
codeine	codeine	nn1
(	(	y
Tylenol	tylenol	np1
2s	2s	mc2
,	,	y
3s	3s	mc2
,	,	y
and	and	cc
4s	4s	mc2
)	)	y
,	,	y
fentanyl	fentanyl	nn1
(	(	y
Duragesic	duragesic	nn1_jj
)	)	y
,	,	y
and	and	cc
morphine	morphine	nn1
(	(	y
MS	ms	nnb
Contin	contin	np1
)	)	y
.	.	y
These	these	dd2
drugs	drug	nn2
are	be	vbr
commonly	commonly	rr
prescribed	prescribe	vvn
for	for	if
acute	acute	jj
pain	pain	nn1
(	(	y
for	for	rex21
example	example	rex22
,	,	y
tooth	tooth	nn1
,	,	y
post-injury	post-injury	nn1_jj
,	,	y
or	or	cc
surgery	surgery	nn1
pain	pain	nn1
)	)	y
or	or	cc
chronic	chronic	jj
pain	pain	nn1
(	(	y
for	for	rex21
example	example	rex22
,	,	y
back	back	nn1_jj@
pain	pain	nn1
or	or	cc
pain	pain	nn1
associated	associate	vvn
with	with	iw
malignancy	malignancy	nn1
)	)	y
.	.	y
Methadone	methadone	vv0_nn1_np1@
,	,	y
which	which	ddq
is	be	vbz
used	use	vvn
both	both	rr
for	for	if
the	the	at
treatment	treatment	nn1
of	of	io
opioid	opioid	jj_nn1
dependence	dependence	nn1
and	and	cc
for	for	if
pain	pain	nn1
,	,	y
is	be	vbz
rising	rise	vvg
as	as	ii
a	a	at1
primary	primary	jj_nn1
drug	drug	nn1
of	of	io
abuse	abuse	nn1
as	as	rr21_rg
well	well	rr22_rr
(	(	y
Maxwell	maxwell	np1
,	,	y
2006	2006	mc
)	)	y
.	.	y
<p>	<p>	y
Statistics	statistics	nn
over	over	ii
the	the	at
past	past	jj
five	five	mc
years	year	nnt2
have	have	vh0
shown	show	vvn
that	that	cst
the	the	at
misuse	misuse	nn1
of	of	io
prescription	prescription	nn1
pain	pain	nn1
medications	medication	nn2
by	by	ii
students	student	nn2
in	in	ii
grades	grade	nn2
8	8	mc
through	through	ii
12	12	mc
continues	continue	vvz
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
,	,	y
alcohol	alcohol	nn1
,	,	y
and	and	cc
steroids	steroids	nn2
has	have	vhz
decreased	decrease	vvn
.	.	y
Data	data	nn
from	from	ii
admissions	admission	nn2
to	to	ii
treatment	treatment	nn1
facilities	facility	nn2
show	show	vv0
that	that	dd1_cst
heroin	heroin	nn1
as	as	ii_csa
a	a	at1
primary	primary	jj_nn1
drug	drug	nn1
of	of	io
choice	choice	nn1
decreased	decrease	vvn_vvd
from	from	ii
2000	2000	mc
to	to	ii
2005	2005	mc
;	;	y
during	during	ii
that	that	dd1
same	same	da
time	time	nnt1
period	period	nn1
,	,	y
admissions	admission	nn2
for	for	if
other	other	jj
opioids	opioid	nn2
increased	increase	vvn_vvd
(	(	y
Center	center	nn1
for	for	if
Substance	substance	nn1
Abuse	abuse	nn1
Research	research	nn1
,	,	y
2007	2007	mc
)	)	y
.	.	y
According	according	ii21
to	to	ii22
the	the	at
National	national	jj
Survey	survey	nn1
on	on	ii
Drug	drug	nn1
Use	use	nn1
and	and	cc
Health	health	nn1
(	(	y
NSDUH	nsduh	np1
)	)	y
report	report	nn1
(	(	y
NSDUH	nsduh	np1_nn1
,	,	y
2006	2006	mc
)	)	y
,	,	y
nonmedical	nonmedical	jj
use	use	nn1
of	of	io
prescription	prescription	nn1
pain	pain	nn1
medications	medication	nn2
has	have	vhz
increased	increase	vvn
among	among	ii
young	young	jj
adults	adult	nn2
ages	age	vvz@_nn2
18	18	mc
to	to	ii
25	25	mc
.	.	y
More	more	dar
people	people	nn
initiated	initiate	vvd_jj@_vvn
use	use	nn1
of	of	io
prescription	prescription	nn1
pain	pain	nn1
relievers	reliever	vvz
in	in	ii
2004	2004	mc
than	than	csn
began	begin	vvd
using	use	vvg
marijuana	marijuana	nn1
or	or	cc
cocaine	cocaine	nn1
.	.	y
Often	often	rr
these	these	dd2
drugs	drug	nn2
are	be	vbr
relatively	relatively	rr
easy	easy	jj
to	to	to
obtain	obtain	vvi
,	,	y
are	be	vbr
viewed	view	vvn
as	as	csa_ii@_rg@
safer	safe	jjr_rrr
than	than	csn
illegal	illegal	jj
drugs	drug	nn2
,	,	y
and	and	cc
are	be	vbr
less	less	rgr
shameful	shameful	jj
to	to	to
use	use	vvi
.	.	y
Although	although	cs
prescription	prescription	nn1
pain	pain	nn1
pills	pill	nn2
are	be	vbr
from	from	ii
the	the	at
same	same	da
class	class	nn1
of	of	io
drugs	drug	nn2
as	as	csa
heroin	heroin	nn1
,	,	y
the	the	at
difficulty	difficulty	nn1
of	of	io
diagnosis	diagnosis	nn1
of	of	io
abuse	abuse	nn1
and	and	cc
dependence	dependence	nn1
on	on	ii
them	them	ppho2
is	be	vbz
increased	increase	vvn
because	because	ii21
of	of	ii22
their	their	appge
legitimate	legitimate	jj
use	use	nn1
and	and	cc
surrounding	surrounding	jj_vvg
misconceptions	misconception	nn2
.	.	y
<p>	<p>	y
National	national	jj
Center	center	nn1
of	of	io
Health	health	nn1
Statistics	statistics	nn
(	(	y
Maxwell	maxwell	np1
,	,	y
2006	2006	mc
)	)	y
data	data	nn
indicated	indicate	vvd_vvn
that	that	dd1_cst
narcotic	narcotic	nn1
analgesics	analgesic	nn2
such	such	ii21
as	as	ii22
hydrocodone	hydrocodone	nn1
,	,	y
oxycodone	oxycodone	vv0_nn1
,	,	y
and	and	cc
methadone	methadone	nn1
were	be	vbdr
more	more	rgr
likely	likely	jj
to	to	to
be	be	vbi
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
or	or	cc
cocaine	cocaine	nn1
.	.	y
The	the	at
213	213	mc
percent	percent	nnu
increase	increase	nn1_vv0
in	in	ii
methadone	methadone	nn1
accidental	accidental	jj
poisoning	poisoning	nn1
deaths	death	nn2
between	between	ii
1999	1999	mc
and	and	cc
2003	2003	mc
was	be	vbdz
associated	associate	vvn
with	with	iw
the	the	at
use	use	nn1
of	of	io
methadone	methadone	nn1
as	as	ii_csa
a	a	at1
pain	pain	nn1
medication	medication	nn1
rather	rather	ii21_cs21@
than	than	ii22_cs22@
in	in	ii
opioid	opioid	jj_nn1
treatment	treatment	nn1
programs	program	nn2
(	(	y
Maxwell	maxwell	np1
,	,	y
2006	2006	mc
)	)	y
.	.	y
Such	such	da
alarming	alarming	jj
statistics	statistics	nn
about	about	ii
the	the	at
increase	increase	nn1
in	in	ii
the	the	at
prevalence	prevalence	nn1
of	of	io
prescription	prescription	nn1
pain	pain	nn1
medication	medication	nn1
misuse	misuse	nn1
with	with	iw
the	the	at
corresponding	corresponding	jj
damage	damage	nn1
to	to	ii
individuals	individual	nn2
and	and	cc
to	to	ii
society	society	nn1
calls	call	vvz_nn2
for	for	if
study	study	nn1
and	and	cc
better	better	jjr
services	service	nn2
.	.	y
<p>	<p>	y
Individuals	individual	nn2
who	who	pnqs
abuse	abuse	vv0@
pain	pain	nn1
medication	medication	nn1
present	present	nn1_vv0@
a	a	at1
unique	unique	jj
population	population	nn1
in	in	ii
their	their	appge
sociodemographic	sociodemographic	jj
characteristics	characteristic	nn2
and	and	cc
drug	drug	nn1
use	use	nn1_vv0
patterns	pattern	nn2
.	.	y
More	more	dar
than	than	csn
half	half	db
of	of	io
the	the	at
new	new	jj
users	user	nn2
of	of	io
prescription	prescription	nn1
pain	pain	nn1
relievers	reliever	vvz
are	be	vbr
female	female	jj
,	,	y
the	the	at
average	average	jj_nn1
age	age	nn1
of	of	io
first	first	md
nonmedical	nonmedical	jj
use	use	nn1
of	of	io
pain	pain	nn1
relievers	reliever	vvz
was	be	vbdz
25	25	mc
,	,	y
and	and	cc
almost	almost	rr
90	90	mc
percent	percent	nnu
of	of	io
new	new	jj
users	user	nn2
are	be	vbr
white	white	jj
(	(	y
NSDUH	nsduh	np1_nn1
,	,	y
2006	2006	mc
)	)	y
.	.	y
This	this	dd1
increase	increase	nn1
in	in	ii
the	the	at
abuse	abuse	nn1
of	of	io
opioids	opioid	nn2
by	by	ii
this	this	dd1
group	group	nn1
raises	raise	vvz
the	the	at
need	need	nn1
to	to	to
target	target	vvi
this	this	dd1
population	population	nn1
for	for	if
treatment	treatment	nn1
and	and	cc
to	to	to
examine	examine	vvi
the	the	at
effectiveness	effectiveness	nn1
of	of	io
existing	existing	jj
treatment	treatment	nn1
modalities	modality	nn2
.	.	y
<p>	<p>	y
L	l	zz1_np1@
:	:	y
BUPRENORPHINE/NALOXONE	buprenorphine/naloxone	vv0_np1_nn1
AS	as	csa_ii
A	a	zz1_at1@
NEW	new	jj
PHARMACOLOGICAL	pharmacological	jj
TREATMENT	treatment	nn1
Buprenorphine/naloxone	buprenorphine/naloxone	nn1_vv0
,	,	y
is	be	vbz
an	a	at1
evidence-based	evidence-based	jj
pharmacological	pharmacological	jj
treatment	treatment	nn1
that	that	cst_dd1
offers	offer	vvz@
a	a	at1
new	new	jj
and	and	cc
different	different	jj
option	option	nn1
for	for	if
treatment	treatment	nn1
of	of	io
opioid	opioid	jj_nn1
dependence	dependence	nn1
.	.	y
This	this	dd1
medication	medication	nn1
blocks	block	vvz@_nn2
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
.	.	y
It	it	pph1
has	have	vhz
been	be	vbn
demonstrated	demonstrate	vvn
to	to	to
be	be	vbi
effective	effective	jj
with	with	iw
heroin	heroin	nn1
dependence	dependence	nn1
(	(	y
Fiellin		np1
et	et	ra21
al.	al	ra22
,	,	y
2002	2002	mc
;	;	y
Ling	ling	nn1
et	et	ra21
al.	al	ra22
,	,	y
1998	1998	mc
;	;	y
Prescrire	prescrire	vv0_np1
Editorial	editorial	jj_nn1
Staff	staff	nn
,	,	y
2006	2006	mc
)	)	y
,	,	y
and	and	cc
studies	study	nn2
are	be	vbr
now	now	rt
being	be	vbg
conducted	conduct	vvn
by	by	ii
the	the	at
National	national	jj
Institute	institute	nn1
on	on	ii
Drug	drug	nn1
Abuse	abuse	nn1
(	(	y
NIDA	nida	np1
)	)	y
to	to	to
demonstrate	demonstrate	vvi
its	its	z'
effectiveness	effectiveness	nn1
with	with	iw
those	those	dd2
dependent	dependent	jj
on	on	ii
prescription	prescription	nn1
pain	pain	nn1
medication	medication	nn1
(	(	y
see	see	vv0
NIDA	nida	np1_nn1
Clinical	clinical	jj
Trials	trial	nn2
Network	network	nn1
at	at	ii
http		nnu
:	:	y
**41;3590;TOOLONG		fu
)	)	y
.	.	y
Beginning	begin	vvg_nn1
in	in	ii
October	october	npm1
2002	2002	mc
,	,	y
physicians	physician	nn2
who	who	pnqs
take	take	vv0
a	a	at1
sanctioned	sanctioned	jj@
course	course	nn1
can	can	vm
prescribe	prescribe	vvi
buprenorphine/naloxone	buprenorphine/naloxone	nn1_vv0
as	as	ii_csa
a	a	at1
sublingual	sublingual	jj
tablet	tablet	nn1
for	for	if
opioid	opioid	jj_nn1
addiction	addiction	nn1
from	from	ii
a	a	at1
private	private	jj
office	office	nn1
rather	rather	ii21_cs21@
than	than	ii22_cs22@
exclusively	exclusively	rr
through	through	ii
specialized	specialized	jj
drug	drug	nn1
treatment	treatment	nn1
centers	center	nn2
.	.	y
This	this	dd1
has	have	vhz
increased	increase	vvn
accessibility	accessibility	nn1
to	to	ii
patients	patient	nn2
and	and	cc
decreased	decreased	jj@_vvd_vvn
stigma	stigma	nn1
associated	associate	vvn
with	with	iw
drug	drug	nn1
treatment	treatment	nn1
.	.	y
<p>	<p>	y
Buprenorphine/naloxone	buprenorphine/naloxone	nn1_vv0
has	have	vhz
numerous	numerous	jj
clinical	clinical	jj
advantages	advantage	nn2
.	.	y
Because	because	ii21
of	of	ii22
its	its	z'
unique	unique	jj
makeup	makeup	nn1
it	it	pph1
can	can	vm
be	be	vbi
used	use	vvn
in	in	ii
two	two	mc
valuable	valuable	jj
ways	way	nn2
:	:	y
detoxification	detoxification	nn1
and	and	cc
stabilization	stabilization	nn1
or	or	cc
maintenance	maintenance	nn1
.	.	y
For	for	if
detoxification	detoxification	nn1
,	,	y
buprenorphine/naloxone	buprenorphine/naloxone	nn1
allows	allow	vvz
for	for	if
alleviation	alleviation	nn1
of	of	io
withdrawal	withdrawal	nn1
symptoms	symptom	nn2
,	,	y
even	even	rr
on	on	ii
an	a	at1
outpatient	outpatient	nn1
basis	basis	nn1
,	,	y
while	while	cs
inhibiting	inhibit	vvg
further	far	jjr@_rrr
use	use	nn1_vv0
and	and	cc
misuse	misuse	nn1
of	of	io
those	those	dd2
drugs	drug	nn2
while	while	cs_vv0%
on	on	ii
the	the	at
medication	medication	nn1
.	.	y
Physical	physical	jj
functioning	functioning	nn1@
is	be	vbz
restored	restore	vvn
quickly	quickly	rr
,	,	y
freeing	free	vvg
the	the	at
person	person	nn1
to	to	to
direct	direct	vvi
energy	energy	nn1
and	and	cc
attention	attention	nn1
to	to	ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
a	a	at1
pharmacologically	pharmacologically	rr
supported	support	vvn_jj@_vvd
stabilization	stabilization	nn1
and	and	cc
maintenance	maintenance	nn1
period	period	nn1
.	.	y
This	this	dd1
intervention	intervention	nn1
provides	provide	vvz
dependent	dependent	jj
individuals	individual	nn2
with	with	iw
an	a	at1
extended	extended	jj@
time	time	nnt1
in	in	ii
which	which	ddq
they	they	pphs2
can	can	vm
accomplish	accomplish	vvi
necessary	necessary	jj
habit	habit	nn1
changes	change	nn2
(	(	y
both	both	db2_rr
cognitive	cognitive	jj
and	and	cc
behavioral	behavioral	nn1_jj
)	)	y
.	.	y
Abstinence	abstinence	nn1
is	be	vbz
supported	support	vvn
because	because	cs
the	the	at
medication	medication	nn1
interrupts	interrupt	nn2
and	and	cc
inhibits	inhibit	vvz
the	the	at
effect	effect	nn1
of	of	io
opioids	opioid	nn2
in	in	ii
the	the	at
brain	brain	nn1
.	.	y
<p>	<p>	y
Buprenorphine/naloxone	buprenorphine/naloxone	nn1_vv0
is	be	vbz
effective	effective	jj
because	because	cs
it	it	pph1
relieves	relieve	vvz
withdrawal	withdrawal	nn1
symptoms	symptom	nn2
,	,	y
does	do	vdz
not	not	xx
make	make	vvi
the	the	at
person	person	nn1
feel	feel	vvi
high	high	jj_rr@
,	,	y
interferes	interfere	vvz
with	with	iw
the	the	at
use	use	nn1
of	of	io
other	other	jj
opioids	opioid	nn2
,	,	y
and	and	cc
is	be	vbz
very	very	rg
difficult	difficult	jj
to	to	to
misuse	misuse	vvi
.	.	y
It	it	pph1
is	be	vbz
the	the	at
physical	physical	jj
withdrawal	withdrawal	nn1
symptoms	symptom	nn2
in	in	ii
opioid	opioid	jj_nn1
addicts	addict	nn2
that	that	cst
significantly	significantly	rr
interfere	interfere	vv0
with	with	iw
discontinuing	discontinue	vvg_jj@
use	use	nn1
of	of	io
the	the	at
drug	drug	nn1
.	.	y
Because	because	cs
buprenorphine/naloxone	buprenorphine/naloxone	nn1
is	be	vbz
a	a	at1
mild	mild	jj
agonist	agonist	nn1
,	,	y
a	a	at1
substance	substance	nn1
abuser	abuser	nn1
does	do	vdz
not	not	xx
need	need	vvi
to	to	to
be	be	vbi
fully	fully	rr
detoxified	detoxify	vvn
to	to	to
receive	receive	vvi
the	the	at
medication	medication	nn1
.	.	y
<p>	<p>	y
Buprenorphine/naloxone	buprenorphine/naloxone	nn1_vv0
is	be	vbz
safer	safe	jjr
and	and	cc
less	less	rgr
prone	prone	jj
to	to	to
abuse	abuse	vvi
than	than	csn
are	be	vbr
other	other	jj
opioids	opioid	nn2
,	,	y
including	including	ii_vvg@
methadone	methadone	nn1
,	,	y
because	because	ii21
of	of	ii22
its	its	z'
ceiling	ceiling	nn1
effect	effect	nn1
.	.	y
Taking	take	vvg
more	more	dar
of	of	io
it	it	pph1
does	do	vdz
not	not	xx
make	make	vvi
a	a	at1
person	person	nn1
"	"	y
higher	high	rrr@_jjr
,	,	y
"	"	y
and	and	cc
it	it	pph1
is	be	vbz
safer	safe	jjr_rrr
because	because	cs
there	there	ex
is	be	vbz
no	no	at
increasing	increasing	jj
effect	effect	nn1
on	on	ii
respiratory	respiratory	jj
depression	depression	nn1
,	,	y
which	which	ddq
is	be	vbz
often	often	rr
the	the	at
cause	cause	nn1
of	of	io
overdose	overdose	nn1
(	(	y
Bowersox	bowersox	np1_nn1
,	,	y
1995	1995	mc
)	)	y
.	.	y
Furthermore	furthermore	rr
,	,	y
it	it	pph1
is	be	vbz
less	less	rgr
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
a	a	at1
heightened	heightened	jj
effect	effect	nn1
by	by	ii
doubling	double	vvg
up	up	rp
with	with	iw
other	other	jj
opioids	opioid	nn2
.	.	y
Buprenorphine/naloxone	buprenorphine/naloxone	nn1_vv0
blocks	block	vvz@_nn2
the	the	at
effects	effect	nn2
of	of	io
other	other	jj
opioids	opioid	nn2
,	,	y
which	which	ddq
means	mean	vvz
that	that	cst
if	if	cs
an	a	at1
individual	individual	nn1_jj
uses	use	vvz
a	a	at1
drug	drug	nn1
such	such	ii21
as	as	ii22
oxycodone	oxycodone	nn1
or	or	cc
heroin	heroin	nn1
while	while	cs
taking	take	vvg
the	the	at
medication	medication	nn1
,	,	y
there	there	ex
is	be	vbz
no	no	at
effect	effect	nn1
from	from	ii
that	that	dd1
drug	drug	nn1
.	.	y
In	in	rr21
addition	addition	rr22
,	,	y
this	this	dd1
medication	medication	nn1
has	have	vhz
a	a	at1
built-in	built-in	jj
mechanism	mechanism	nn1
that	that	cst_dd1
discourages	discourage	vvz
misuse	misuse	nn1
through	through	ii
crushing	crush	vvg_jj
,	,	y
snorting	snort	vvg
,	,	y
or	or	cc
injecting	inject	vvg
.	.	y
If	if	cs
used	use	vvn
in	in	ii
any	any	dd
of	of	io
these	these	dd2
ways	way	nn2
,	,	y
the	the	at
effects	effect	nn2
of	of	io
buprenorphine	buprenorphine	nn1
are	be	vbr
not	not	xx
felt	feel	vvn
and	and	cc
the	the	at
naloxone	naloxone	nn1
(	(	y
which	which	ddq
has	have	vhz
no	no	at
clinical	clinical	jj
effect	effect	nn1
when	when	cs_rrq
taken	take	vvn
sublingually	sublingually	rr
as	as	csa_rg@
prescribed	prescribe	vvn_jj
)	)	y
is	be	vbz
felt	feel	vvn
in	in	ii_rr21
full	full	jj_rr22
force	force	nn1_vv0@
,	,	y
causing	cause	vvg
the	the	at
individual	individual	jj_nn1
to	to	to
go	go	vvi
into	into	ii
immediate	immediate	jj
withdrawal	withdrawal	nn1
.	.	y
<p>	<p>	y
L	l	zz1_np1@
:	:	y
CLINICAL	clinical	jj
TREATMENT	treatment	nn1
With	with	iw
the	the	at
growing	growing	jj
trend	trend	nn1
of	of	io
dependence	dependence	nn1
on	on	ii
prescription	prescription	nn1
pain	pain	nn1
medications	medication	nn2
and	and	cc
the	the	at
increase	increase	nn1
in	in	ii
use	use	nn1
of	of	io
pharmacological	pharmacological	jj
treatments	treatment	nn2
of	of	io
addictions	addiction	nn2
,	,	y
new	new	jj
treatment	treatment	nn1
models	model	nn2
are	be	vbr
needed	need	vvn
to	to	to
address	address	vvi
and	and	cc
support	support	vvi
long-term	long-term	jj
recovery	recovery	nn1
.	.	y
At	at	ii
the	the	at
West	west	np1
Virginia	virginia	np1
University	university	nn1
Department	department	nn1
of	of	io
Behavioral	behavioral	jj_np1_nn1
Medicine	medicine	nn1
,	,	y
a	a	at1
model	model	nn1
for	for	if
treatment	treatment	nn1
of	of	io
opioid	opioid	jj_nn1
dependence	dependence	nn1
that	that	cst_dd1
uses	use	vvz
a	a	at1
combination	combination	nn1
of	of	io
two	two	mc
evidence-based	evidence-based	jj
treatments	treatment	nn2
is	be	vbz
being	be	vbg
offered	offer	vvn
to	to	ii
opioid-dependent	opioid-dependent	jj
clients	client	nn2
.	.	y
The	the	at
majority	majority	nn1
of	of	io
these	these	dd2
clients	client	nn2
are	be	vbr
dependent	dependent	jj
on	on	ii
prescription	prescription	nn1
pain	pain	nn1
pills	pill	nn2
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
includes	include	vvz
treatment	treatment	nn1
with	with	iw
buprenorphine/		nn1
naloxone	naloxone	nn1
and	and	cc
12-step	12-step	jj_nn1
facilitation	facilitation	nn1
therapy	therapy	nn1
(	(	y
Nowinski	nowinski	np1_nn1
,	,	y
Baker	baker	np1
,	,	y
&;		null
Carroll	carroll	np1
,	,	y
1994	1994	mc
)	)	y
.	.	y
During	during	ii
the	the	at
first	first	md
half	half	db_nn1@
hour	hour	nnt1
of	of	io
a	a	at1
weekly	weekly	jj
90-minute	90-minute	jj
group	group	nn1
,	,	y
clients	client	nn2
see	see	vv0
the	the	at
physician	physician	nn1
,	,	y
report	report	nn1_vv0@
on	on	ii
required	required	jj
12-step	12-step	jj_nn1
meeting	meeting	nn1_vvg
attendance	attendance	nn1
,	,	y
complete	complete	jj_vv0
random	random	jj
drug	drug	nn1
screens	screen	nn2
,	,	y
and	and	cc
receive	receive	vv0
education	education	nn1
about	about	ii
the	the	at
medication	medication	nn1
.	.	y
During	during	ii
the	the	at
subsequent	subsequent	jj
60	60	mc
minutes	minute	nnt2
they	they	pphs2
engage	engage	vv0
in	in	ii_rp@
a	a	at1
group	group	nn1
that	that	cst_dd1
teaches	teach	vvz
about	about	ii_rp@
concepts	concept	nn2
important	important	jj
to	to	ii
12-step	12-step	jj_nn1
participation	participation	nn1
.	.	y
Objectives	objective	nn2
of	of	io
12-step	12-step	jj_nn1
facilitation	facilitation	nn1
therapy	therapy	nn1
include	include	vv0
identifying	identify	vvg_jj@
and	and	cc
changing	changing	jj_vvg
cognitions	cognition	nn2
related	relate	vvn_vvd
to	to	ii
drug	drug	nn1
use	use	nn1_vv0
,	,	y
learning	learn	vvg
to	to	to
deal	deal	vvi
with	with	iw
emotional	emotional	jj
states	state	nn2
that	that	cst
contribute	contribute	vv0
to	to	to
use	use	vvi
,	,	y
developing	develop	vvg_jj
behaviors	behavior	nn2
that	that	cst_dd1
support	support	vv0_nn1
abstinence	abstinence	nn1
,	,	y
increasing	increase	vvg_jj
healthy	healthy	jj
social	social	jj
and	and	cc
relational	relational	jj
supports	support	nn2
,	,	y
and	and	cc
taking	take	vvg
part	part	nn1
in	in	ii
activities	activity	nn2
that	that	cst
enhance	enhance	vv0
hope	hope	nn1_vv0
and	and	cc
trust	trust	nn1_vv0
.	.	y
Journaling	journaling	np1@_vvg_nn1@
is	be	vbz
encouraged	encourage	vvn
as	as	ii
a	a	at1
way	way	nn1
of	of	io
increasing	increasing	jj_vvg
engagement	engagement	nn1
and	and	cc
self-reflection	self-reflection	nn1_jj
.	.	y
This	this	dd1
60-minute	60-minute	jj
segment	segment	nn1
ends	end	vvz_nn2
with	with	iw
a	a	at1
commitment	commitment	nn1
from	from	ii
group	group	nn1
members	member	nn2
regarding	regarding	ii_vvg
their	their	appge
recovery	recovery	nn1
activities	activity	nn2
for	for	if
the	the	at
week	week	nnt1
.	.	y
Clients	client	nn2
participate	participate	vv0
in	in	ii_rp@
the	the	at
weekly	weekly	jj
group	group	nn1
until	until	cs
they	they	pphs2
have	have	vh0
90	90	mc
days	day	nnt2
of	of	io
abstinence	abstinence	nn1
and	and	cc
a	a	at1
sponsor	sponsor	nn1
.	.	y
At	at	ii
that	that	dd1
time	time	nnt1
they	they	pphs2
are	be	vbr
referred	refer	vvn
to	to	ii
a	a	at1
monthly	monthly	jj
group	group	nn1
that	that	cst_dd1
consists	consist	vvz
of	of	io
meeting	meet	vvg_nn1
with	with	iw
the	the	at
physician	physician	nn1
,	,	y
reporting	report	vvg
on	on	ii_rp@
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
treatment	treatment	nn1
planning	planning	nn1_vvg
addresses	address	vvz_nn2
issues	issue	nn2
such	such	ii21
as	as	ii22
length	length	nn1
of	of	io
treatment	treatment	nn1
and	and	cc
other	other	jj
specialized	specialized	jj
needs	need	nn2
.	.	y
<p>	<p>	y
L	l	zz1_np1@
:	:	y
IMPLICATIONS	implication	nn2
FOR	for	if
PRACTICE	practice	nn1
For	for	if
social	social	jj
workers	worker	nn2
addressing	address	vvg
the	the	at
problem	problem	nn1
of	of	io
prescription	prescription	nn1
pain	pain	nn1
pill	pill	nn1
dependence	dependence	nn1
,	,	y
there	there	ex
are	be	vbr
four	four	mc
primary	primary	jj
areas	area	nn2
of	of	io
intervention	intervention	nn1
:	:	y
treatment	treatment	nn1
,	,	y
education	education	nn1
,	,	y
advocacy	advocacy	nn1
,	,	y
and	and	cc
research	research	nn1
.	.	y
Treatment	treatment	nn1
should	should	vm
be	be	vbi
provided	provide	vvn
through	through	ii
a	a	at1
multidisciplinary	multidisciplinary	nn1_jj
,	,	y
abstinence-based	abstinence-based	jj_nn1
approach	approach	nn1
,	,	y
with	with	iw
physicians	physician	nn2
and	and	cc
social	social	jj
workers	worker	nn2
collaborating	collaborate	vvg
by	by	ii
using	use	vvg
evidence-based	evidence-based	jj_nn1
treatments	treatment	nn2
such	such	ii21
as	as	ii22
those	those	dd2
described	describe	vvn_vvd
earlier	early	rrr
.	.	y
<p>	<p>	y
Education	education	nn1
is	be	vbz
essential	essential	jj
to	to	to
refer	refer	vvi
or	or	cc
provide	provide	vvi
effective	effective	jj
treatment	treatment	nn1
to	to	ii
this	this	dd1
population	population	nn1
.	.	y
Social	social	jj
workers	worker	nn2
need	need	vv0
to	to	to
be	be	vbi
knowledgeable	knowledgeable	jj
about	about	ii
the	the	at
increase	increase	nn1
in	in	ii
the	the	at
dependence	dependence	nn1
on	on	ii
prescription	prescription	nn1
pain	pain	nn1
pills	pill	nn2
and	and	cc
about	about	ii
the	the	at
role	role	nn1
that	that	cst_dd1
buprenorphine/naloxone	buprenorphine/naloxone	nn1_vv0
can	can	vm
play	play	vvi
in	in	ii
the	the	at
recovery	recovery	nn1
process	process	nn1_vv0
,	,	y
including	including	ii_vvg@
its	its	z'
strengths	strength	nn2
and	and	cc
limitations	limitation	nn2
.	.	y
The	the	at
goal	goal	nn1
of	of	io
buprenorphine/naloxone	buprenorphine/naloxone	nn1
therapy	therapy	nn1
in	in	ii
the	the	at
treatment	treatment	nn1
of	of	io
opioid	opioid	jj_nn1
addiction	addiction	nn1
is	be	vbz
to	to	to
prevent	prevent	vvi
withdrawal	withdrawal	nn1
symptoms	symptom	nn2
and	and	cc
to	to	to
suppress	suppress	vvi
cravings	craving	nn2
for	for	if
opioids	opioid	nn2
.	.	y
The	the	at
medication	medication	nn1
,	,	y
however	however	rr
,	,	y
does	do	vdz
not	not	xx
treat	treat	vvi
addictive	addictive	jj
patterns	pattern	nn2
and	and	cc
behaviors	behavior	nn2
.	.	y
It	it	pph1
gives	give	vvz
the	the	at
addicted	addicted	jj@
person	person	nn1
the	the	at
support	support	nn1
to	to	to
stop	stop	vvi
using	use	vvg
drugs	drug	nn2
,	,	y
but	but	ccb
it	it	pph1
does	do	vdz
not	not	xx
provide	provide	vvi
social	social	jj
support	support	nn1
systems	system	nn2
or	or	cc
alternate	alternate	jj_vv0
patterns	pattern	nn2
of	of	io
behavior	behavior	nn1
and	and	cc
cognitions	cognition	nn2
that	that	cst
are	be	vbr
needed	need	vvn
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
individual	individual	nn1
can	can	vm
just	just	rr
stop	stop	vvi
using	use	vvg
the	the	at
drug	drug	nn1
the	the	at
problem	problem	nn1
will	will	vm
be	be	vbi
solved	solve	vvn
.	.	y
To	to	ii
the	the	at
nave	nave	nn1
user	user	nn1
and	and	cc
her	her	ppho1_appge
or	or	cc
his	his	appge
family	family	nn1
,	,	y
the	the	at
social	social	jj
systems	system	nn2
,	,	y
and	and	cc
even	even	rr
the	the	at
prescribing	prescribing	nn1@
clinician	clinician	nn1
,	,	y
buprenorphine/naloxone	buprenorphine/naloxone	nn1_vv0
may	may	vm
give	give	vvi
the	the	at
illusion	illusion	nn1
of	of	io
"	"	y
fixing	fix	vvg
"	"	y
the	the	at
problem	problem	nn1
by	by	ii
simply	simply	rr
helping	help	vvg
an	a	at1
individual	individual	jj_nn1
to	to	to
stop	stop	vvi
using	use	vvg
opioids	opioid	nn2
.	.	y
All	all	db_rr@
can	can	vm
be	be	vbi
seduced	seduce	vvn
into	into	ii
believing	believe	vvg
that	that	cst_dd1
once	once	cs@_rr
the	the	at
drug	drug	nn1
is	be	vbz
out	out	ii21
of	of	ii22
a	a	at1
person	person	nn1
's	's	ge
system	system	nn1
the	the	at
individual	individual	nn1_jj
no	no	rr21
longer	long	rr22
suffers	suffer	vvz
the	the	at
negative	negative	jj
effects	effect	nn2
of	of	io
drug	drug	nn1
addiction	addiction	nn1
.	.	y
<p>	<p>	y
Advocacy	advocacy	nn1
is	be	vbz
needed	need	vvn
to	to	to
ensure	ensure	vvi
the	the	at
effective	effective	jj
use	use	nn1
of	of	io
this	this	dd1
medication	medication	nn1
and	and	cc
to	to	to
inhibit	inhibit	vvi
its	its	z'
misuse	misuse	nn1
.	.	y
Because	because	cs
it	it	pph1
is	be	vbz
less	less	rgr
strictly	strictly	rr
regulated	regulate	vvn_jj@
than	than	csn
methadone	methadone	nn1_vv0
,	,	y
buprenorphine/naloxone	buprenorphine/naloxone	nn1_vv0
has	have	vhz
an	a	at1
initial	initial	jj_nn1
advantage	advantage	nn1
of	of	io
availability	availability	nn1
.	.	y
However	however	rr
,	,	y
this	this	dd1
availability	availability	nn1
has	have	vhz
its	its	z'
downside	downside	nn1
.	.	y
Without	without	iw
the	the	at
necessary	necessary	jj
support	support	nn1
and	and	cc
education	education	nn1
,	,	y
clients	client	nn2
are	be	vbr
at	at	ii
risk	risk	nn1
of	of	io
not	not	xx
receiving	receive	vvg
needed	need	vvn_vvd
therapy	therapy	nn1
and	and	cc
emphasis	emphasis	nn1
on	on	ii
life	life	nn1
changes	change	nn2
.	.	y
A	a	at1_zz1
combined	combined	jj
medical	medical	jj
management	management	nn1
and	and	cc
abstinence-based	abstinence-based	jj
therapeutic	therapeutic	jj
approach	approach	nn1
offers	offer	nn2_vvz@
both	both	rr_db2
the	the	at
physiological	physiological	jj
support	support	nn1
for	for	if
detoxification	detoxification	nn1
and	and	cc
maintenance	maintenance	nn1
and	and	cc
the	the	at
support	support	nn1
for	for	if
lifestyle	lifestyle	nn1
changes	change	vvz@_nn2
necessary	necessary	jj
for	for	if
enduring	enduring	jj_vvg
recovery	recovery	nn1
.	.	y
Long-term	long-term	jj
relief	relief	nn1
from	from	ii
drug	drug	nn1
addiction	addiction	nn1
can	can	vm
be	be	vbi
achieved	achieve	vvn
by	by	ii
treating	treat	vvg
the	the	at
withdrawal	withdrawal	nn1
symptoms	symptom	nn2
and	and	cc
supporting	support	vvg
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
emotional	emotional	jj
responses	response	nn2
,	,	y
and	and	cc
family	family	nn1
and	and	cc
social	social	jj
systems	system	nn2
that	that	cst
support	support	vv0
long-term	long-term	jj
recovery	recovery	nn1
.	.	y
<p>	<p>	y
Another	another	dd1
disadvantage	disadvantage	nn1
of	of	io
less	less	rgr
strict	strict	jj
regulation	regulation	nn1
of	of	io
buprenorphine/naloxone	buprenorphine/naloxone	nn1
is	be	vbz
the	the	at
increase	increase	nn1
in	in	ii
its	its	z'
street	street	nn1
availability	availability	nn1
.	.	y
Although	although	cs
the	the	at
drug	drug	nn1
has	have	vhz
some	some	dd
inherent	inherent	jj
safety	safety	nn1
mechanisms	mechanism	nn2
,	,	y
it	it	pph1
still	still	rr
can	can	vm
be	be	vbi
bartered	barter	vvn_jj
and	and	cc
sold	sell	vvn_vvd
for	for	if
other	other	jj
drugs	drug	nn2
.	.	y
This	this	dd1
medication	medication	nn1
can	can	vm
be	be	vbi
misused	misuse	vvn
in	in	ii
a	a	at1
way	way	nn1
that	that	cst_dd1
supports	support	vvz
ongoing	ongoing	jj
addiction	addiction	nn1
to	to	ii
other	other	jj
drugs	drug	nn2
of	of	io
abuse	abuse	nn1
.	.	y
For	for	rex21
example	example	rex22
,	,	y
an	a	at1
individual	individual	nn1
may	may	vm
use	use	vvi
buprenorphine/naloxone	buprenorphine/naloxone	nn1_vv0
to	to	to
prevent	prevent	vvi
withdrawal	withdrawal	nn1
during	during	ii
a	a	at1
time	time	nnt1
that	that	cst
he	he	pphs1
or	or	cc
she	she	pphs1
can	can	vm
not	not	xx
find	find	vvi
or	or	cc
afford	afford	vvi
the	the	at
drug	drug	nn1
of	of	io
choice	choice	nn1
,	,	y
only	only	rr
to	to	ii
return	return	nn1
to	to	ii
the	the	at
use	use	nn1
of	of	io
that	that	dd1
drug	drug	nn1
when	when	cs_rrq
it	it	pph1
becomes	become	vvz
available	available	jj
.	.	y
It	it	pph1
can	can	vm
also	also	rr
be	be	vbi
used	use	vvn
during	during	ii
the	the	at
week	week	nnt1
,	,	y
with	with	iw
the	the	at
plan	plan	nn1
to	to	to
return	return	vvi
to	to	ii
"	"	y
partying	party	vvg
"	"	y
on	on	ii
the	the	at
weekend	weekend	nnt1
.	.	y
<p>	<p>	y
Research	research	nn1
is	be	vbz
needed	need	vvn
to	to	to
increase	increase	vvi
social	social	jj
workers	worker	nn2
'	'	ge
understanding	understanding	nn1
of	of	io
the	the	at
successful	successful	jj
tools	tool	nn2
and	and	cc
protocols	protocol	nn2
that	that	cst
are	be	vbr
effective	effective	jj
for	for	if
the	the	at
treatment	treatment	nn1
of	of	io
prescription	prescription	nn1
drug	drug	nn1
abuse	abuse	nn1
.	.	y
For	for	rex21
example	example	rex22
,	,	y
research	research	nn1
could	could	vm
promote	promote	vvi
understanding	understanding	nn1
of	of	io
what	what	ddq
doses	dose	nn2
of	of	io
buprenorphine/		nn1
naloxone	naloxone	nn1
are	be	vbr
most	most	rgt
effective	effective	jj
on	on	ii
the	the	at
basis	basis	nn1
of	of	io
a	a	at1
person	person	nn1
's	's	ge
level	level	nn1
of	of	io
tolerance	tolerance	nn1
of	of	io
opioids	opioid	nn2
.	.	y
In	in	rr21
addition	addition	rr22
,	,	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
to	to	to
best	best	rrt_jjt
promote	promote	vvi
long-term	long-term	jj
abstinence	abstinence	nn1
would	would	vm
provide	provide	vvi
more	more	rgr_dar
clear	clear	jj
treatment	treatment	nn1
protocols	protocol	nn2
.	.	y
<p>	<p>	y
Buprenorphine/naloxone	buprenorphine/naloxone	nn1_vv0
is	be	vbz
an	a	at1
exciting	exciting	jj
new	new	jj
tool	tool	nn1
and	and	cc
,	,	y
as	as	csa
is	be	vbz
characteristic	characteristic	jj_nn1
of	of	io
all	all	db
tools	tool	nn2
,	,	y
it	it	pph1
is	be	vbz
used	use	vvn_jj
best	best	vv0%
with	with	iw
an	a	at1
understanding	understanding	nn1
of	of	io
its	its	z'
limitations	limitation	nn2
.	.	y
Although	although	cs
at	at	ii
times	time	nnt2
history	history	nn1
has	have	vhz
shown	show	vvn
failure	failure	nn1
of	of	io
promise	promise	nn1
with	with	iw
new	new	jj
pharmacological	pharmacological	jj
interventions	intervention	nn2
,	,	y
medications	medication	nn2
are	be	vbr
showing	show	vvg
an	a	at1
increasing	increasing	jj
role	role	nn1
in	in	ii
the	the	at
treatment	treatment	nn1
of	of	io
addiction	addiction	nn1
to	to	ii
various	various	jj
drugs	drug	nn2
.	.	y
Sometimes	sometimes	rt
the	the	at
failure	failure	nn1
of	of	io
new	new	jj
promise	promise	nn1
is	be	vbz
born	born	vvn
out	out	ii21
of	of	ii22
misunderstanding	misunderstanding	nn1
of	of	io
the	the	at
best	best	jjt
use	use	nn1
of	of	io
a	a	at1
new	new	jj
intervention	intervention	nn1
.	.	y
Buprenorphine/naloxone	buprenorphine/naloxone	nn1_vv0
can	can	vm
be	be	vbi
used	use	vvn
for	for	if
both	both	rr
detoxification	detoxification	nn1
and	and	cc
maintenance	maintenance	nn1
,	,	y
but	but	ccb
it	it	pph1
does	do	vdz
not	not	xx
do	do	vdi
the	the	at
hard	hard	jj
work	work	nn1
of	of	io
cognition	cognition	nn1
and	and	cc
habit	habit	nn1
change	change	vv0_nn1
that	that	dd1_cst
is	be	vbz
so	so	rg_rr
important	important	jj
for	for	if
overall	overall	jj_nn1
success	success	nn1
in	in	ii
the	the	at
treatment	treatment	nn1
of	of	io
drug	drug	nn1
addiction	addiction	nn1
.	.	y
<p>	<p>	y
Drug	drug	nn1
dependence	dependence	nn1
is	be	vbz
accompanied	accompany	vvn
by	by	ii
habits	habit	nn2
that	that	cst_dd1
must	must	vm
be	be	vbi
changed	change	vvn
to	to	to
support	support	vvi
long-term	long-term	jj
health	health	nn1
.	.	y
Through	through	ii
an	a	at1
understanding	understanding	nn1
of	of	io
the	the	at
changing	changing	jj
trends	trend	nn2
in	in	ii
drugs	drug	nn2
of	of	io
abuse	abuse	nn1
and	and	cc
the	the	at
strengths	strength	nn2
and	and	cc
limitations	limitation	nn2
of	of	io
new	new	jj
evidence-based	evidence-based	jj_nn1
treatments	treatment	nn2
,	,	y
social	social	jj
workers	worker	nn2
can	can	vm
support	support	vvi
the	the	at
use	use	nn1
of	of	io
these	these	dd2
interventions	intervention	nn2
in	in	ii
a	a	at1
way	way	nn1
that	that	cst_dd1
is	be	vbz
most	most	rgt
advantageous	advantageous	jj
to	to	ii
their	their	appge
clients	client	nn2
and	and	cc
society	society	nn1
.	.	y
Identification	identification	nn1
of	of	io
addiction	addiction	nn1
in	in	ii
vulnerable	vulnerable	jj
populations	population	nn2
and	and	cc
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
for	for	if
the	the	at
treatment	treatment	nn1
of	of	io
this	this	dd1
destructive	destructive	jj
disease	disease	nn1
and	and	cc
pervasive	pervasive	jj
societal	societal	jj
problem	problem	nn1
.	.	y
<p>	<p>	y
L	l	zz1_np1@
:	:	y
REFERENCES	reference	nn2_vvz@
--		zz
Bowersox	bowersox	nn1_np1
,	,	y
J.	xx_j	np1
(	(	y
1995	1995	mc
)	)	y
.	.	y
Buprenorphine/naloxone	buprenorphine/naloxone	nn1_vv0
may	may	vm
soon	soon	rr
be	be	vbi
heroin	heroin	nn1
treatment	treatment	nn1
option	option	nn1
.	.	y
NIDA	nida	np1_nn1
Notes	note	nn2_vvz@
,	,	y
10(1)	10(1)	fo
.	.	y
Retrieved	retrieve	vvn_jj@_vvd
November	november	npm1
10	10	mc
,	,	y
2007	2007	mc
,	,	y
from	from	ii
http		nnu
:	:	y
**53;3633;TOOLONG		fu
<p>	<p>	y
--		zz
Center	center	nn1
for	for	if
Substance	substance	nn1
Abuse	abuse	nn1
Research	research	nn1
.	.	y
(	(	y
2007	2007	mc
)	)	y
.	.	y
National	national	jj
treatment	treatment	nn1
admissions	admission	nn2
for	for	if
primary	primary	jj_nn1
abuse	abuse	nn1
of	of	io
heroin	heroin	nn1
decrease	decrease	nn1_vv0
:	:	y
Other	other	jj
opiates	opiate	nn2
and	and	cc
methamphetamine	methamphetamine	vv0_nn1
increase	increase	nn1
.	.	y
Retrieved	retrieve	vvn_jj@_vvd
March	march	npm1
20	20	mc
,	,	y
2007	2007	mc
,	,	y
from	from	ii
**48;3688;TOOLONG		nnu
<p>	<p>	y
--		zz
Fiellin		np1_nn1@
,	,	y
D.A.	da	np1
,	,	y
Pantalon	pantalon	np1_nn1
,	,	y
M.V.	m.v	nnb
,	,	y
Pakes	pakes	np2_nn2@_vvz@
,	,	y
U.	u	np1
P.	xx_p	np1
,	,	y
O'Connor	o'connor	np1
,	,	y
E	e	zz1_np1@
G.	g	np1_nnu@
,	,	y
Chawarski		np1_nn1
,	,	y
M.	m	nn1
,	,	y
&;		null
Schottenfeld	schottenfeld	np1_vv0_nn1
,	,	y
R.	xx_r	np1
S.	s	np1
(	(	y
2002	2002	mc
)	)	y
.	.	y
Treatment	treatment	nn1
of	of	io
heroin	heroin	nn1
dependence	dependence	nn1
with	with	iw
buprenorphine	buprenorphine	nn1
in	in	ii
primary	primary	jj_nn1
care	care	nn1
.	.	y
American	american	jj
Journal	journal	nn1
of	of	io
Drug	drug	nn1
and	and	cc
Alcohol	alcohol	nn1
Abuse	abuse	nn1
,	,	y
28(2)	28(2)	fo
,	,	y
231-241	231-241	mcmc
.	.	y
<p>	<p>	y
--		zz
Ling	ling	nn1
,	,	y
W	w	zz1
,	,	y
Charuvastra		np1
,	,	y
C.	c	np1_zz1@
,	,	y
Collins	collins	np1
,	,	y
J.	xx_j	np1
F.	f	np1
,	,	y
Batki		np1_nn1
,	,	y
S.	s	np1
,	,	y
Brown	brown	np1
,	,	y
L.	l	np1
S.	s	np1
,	,	y
Kintaudi		np1
,	,	y
P.	xx_p	np1
,	,	y
Wesson	wesson	np1
,	,	y
D.	d	np1
R.	xx_r	np1
,	,	y
McNicholas	mcnicholas	np1
,	,	y
L.	l	np1
,	,	y
Tusel		np1
,	,	y
D.J.	d.j	np1
,	,	y
Malkerneker		np1_nn1
,	,	y
U.	u	np1
,	,	y
Renner	renner	np1_nn1
,	,	y
J.A.	ja	np1
,	,	y
Jr.	jr	np1
,	,	y
Santos	santos	np1
,	,	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
,	,	y
Stine	stine	np1
,	,	y
S.	s	np1
,	,	y
Wang	wang	np1
,	,	y
Wang	wang	np1
,	,	y
&;		null
Segal	segal	np1
,	,	y
D.	d	np1
(	(	y
1998	1998	mc
)	)	y
.	.	y
Buprenorphine	buprenorphine	vv0_nn1
maintenance	maintenance	nn1
treatment	treatment	nn1
of	of	io
opiate	opiate	nn1
dependence	dependence	nn1
:	:	y
A	a	at1@_zz1
multicenter	multicenter	jjr_vv0
randomized	randomized	jj@_vvd
clinical	clinical	jj
trial	trial	nn1
.	.	y
Addiction	addiction	npx
,	,	y
93	93	mc
,	,	y
475-486	475-486	mcmc
.	.	y
<p>	<p>	y
--		zz
Maxwell	maxwell	np1
,	,	y
J.	xx_j	np1
C.	c	np1
(	(	y
2006	2006	mc
)	)	y
.	.	y
Trends	trend	nn2
in	in	ii
the	the	at
abuse	abuse	nn1
of	of	io
prescription	prescription	nn1
drags	drag	vvz
.	.	y
Austin	austin	np1
,	,	y
TX	tx	np1
:	:	y
Gulf	gulf	np1
Coast	coast	nn1
Addiction	addiction	npx
Technology	technology	nn1
Transfer	transfer	nn1_vv0
Center	center	nn1
(	(	y
GCATTC		np1
)	)	y
.	.	y
Retrieved	retrieve	vvn_jj@_vvd
January	january	npm1
15	15	mc
,	,	y
2007	2007	mc
,	,	y
from	from	ii
www.utattc.net		nnu
<p>	<p>	y
--		zz
National	national	jj
Survey	survey	nn1
on	on	ii
Drug	drug	nn1
Use	use	nn1
and	and	cc
Health	health	nn1
.	.	y
(	(	y
2006	2006	mc
)	)	y
.	.	y
Nomnedical	nomnedical	jj
users	user	nn2
of	of	io
pain	pain	nn1
relievers	reliever	vvz
:	:	y
Characteristics	characteristic	nn2
of	of	io
recent	recent	jj
initiates	initiate	nn2%_vvz
.	.	y
Office	office	nn1
of	of	io
Applied	applied	jj
Studies	study	nn2
,	,	y
Substance	substance	nn1
Abuse	abuse	nn1
and	and	cc
Mental	mental	jj
Health	health	nn1
Administration	administration	nn1
(	(	y
SAMHSA	samhsa	np1
)	)	y
.	.	y
Retrieved	retrieve	vvn_jj@_vvd
January	january	npm1
15	15	mc
,	,	y
2007	2007	mc
,	,	y
from	from	ii
http		nnu
:	:	y
//www.oas.samhsa.gov		fu
<p>	<p>	y
--		zz
Nowinski	nowinski	nn1_np1_nn2@
,	,	y
J.	xx_j	np1
,	,	y
Baker	baker	np1
,	,	y
S.	s	np1
,	,	y
&;		null
Carroll	carroll	np1
,	,	y
K.	k	np1
M.	m	nn1_nnu@
(	(	y
1994	1994	mc
)	)	y
.	.	y
Twelve	twelve	mc
step	step	nn1_vv0
facilitation	facilitation	nn1
therapy	therapy	nn1
manual	manual	nn1
:	:	y
A	a	zz1_at1@
clinical	clinical	jj
research	research	nn1
guide	guide	nn1_vv0
for	for	if
therapists	therapist	nn2
treating	treat	vvg
individuals	individual	nn2
with	with	iw
alcohol	alcohol	nn1
abuse	abuse	nn1
and	and	cc
dependence	dependence	nn1
(	(	y
NIH	nih	np1_nn1
Publication	publication	nn1
No	no	xx
94-3722		mcmc
)	)	y
.	.	y
Washington	washington	np1
,	,	y
DC	dc	np1
:	:	y
U.S.	us	np1
Department	department	nn1
of	of	io
Health	health	nn1
and	and	cc
Human	human	jj_nn1
Services	service	nn2
,	,	y
National	national	jj
Institute	institute	nn1
on	on	ii
Alcohol	alcohol	nn1
Abuse	abuse	nn1
and	and	cc
Alcoholism	alcoholism	nn1
.	.	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
Buprenorphine	buprenorphine	vv0_nn1
replacement	replacement	nn1
therapy	therapy	nn1
:	:	y
A	a	zz1_at1@
confirmed	confirmed	jj@
benefit	benefit	nn1
.	.	y
Prescrire	prescrire	vv0
International	international	jj
,	,	y
15(82)		fo
,	,	y
64-70	64-70	mcmc
.	.	y
<p>	<p>	y
Original	original	jj
manuscript	manuscript	nn1
received	receive	vvd_vvn
March	march	npm1
15	15	mc
,	,	y
2007	2007	mc
<p>	<p>	y
Final	final	jj_nn1
revision	revision	nn1
received	receive	vvd_vvn
November	november	npm1
16	16	mc
,	,	y
2007	2007	mc
<p>	<p>	y
Accepted	accepted	jj_vvn
January	january	npm1
30	30	mc
,	,	y
2008	2008	mc
<p>	<p>	y
By	by	ii
Marilyn	marilyn	np1
H.	h	np1
Byrne	byrne	np1
;	;	y
Laura	laura	np1
Lander	lander	nn1
and	and	cc
Martha	martha	np1
Ferris	ferri	np1
<p>	<p>	y
Marilyn	marilyn	np1
H.	h	np1
Byrne	byrne	np1
,	,	y
ACSW	acsw	np1_vv0_nn1
,	,	y
is	be	vbz
associate	associate	jj
professor	professor	nn1
,	,	y
and	and	cc
Laura	laura	np1
Lander	lander	nn1
,	,	y
MSW	msw	np1
,	,	y
and	and	cc
Martha	martha	np1
Ferris	ferri	np1
,	,	y
MSW	msw	np1
,	,	y
are	be	vbr
staff	staff	nn
therapists	therapist	nn2
,	,	y
Department	department	nn1
of	of	io
Behavioral	behavioral	jj_np1_nn1
Medicine	medicine	nn1
&;		null
Psychiatry	psychiatry	nn1_np1
,	,	y
West	west	np1
Virginia	virginia	np1
University	university	nn1
,	,	y
930	930	mc
Chestnut	chestnut	np1
Ridge	ridge	np1
Road	road	nnl1
,	,	y
Morgantown	morgantown	np1
,	,	y
WV	wv	np1
26505	26505	mc
;	;	y
e-mail	e-mail	nn1_vv0@
:	:	y
mbyrne@hsc.wvu.edu		fo
.	.	y
<p>	<p>	y
